Abstract
Objectives
Qualitative studies nested within clinical trials can provide insight into the treatment experience, how this evolves over time and where improved supportive care is required. The purpose of this qualitative study is to describe the lived experiences of men with advanced prostate cancer participating in the TheraP trial; a randomised trial of 177Lu-PSMA-617 compared with cabazitaxel chemotherapy.
Methods
Fifteen men with advanced prostate cancer were recruited from the TheraP clinical trial with interviews conducted at three timepoints during the trial. An interpretative phenomenological approach was used, and interviews analysed using thematic analysis. This research paper reports the results from the mid-point, conclusion and follow up interviews, focusing specifically on participants’ experiences of trial participation.
Results
Three themes were identified representing the lived experiences of men with advanced prostate cancer participating in the TheraP trial: (1) facing limited options; (2) anticipating outcomes and (3) coping with health changes.
Conclusions
Men who enrol in clinical trial of anti-neoplastic treatments for prostate cancer need targeted psychological and supportive care that includes attention to unique aspects of the experience of having prostate cancer and being in a clinical trial. As part of their trial experience, men with advanced prostate cancer need to be regularly assessed for survivorship needs, fully informed, supported and referred to services for regular care and support across the trajectory of their disease.
Trial registration
NCT03392428. Registered on 8 January 2018 (ANZUP1603).
Publisher
Public Library of Science (PLoS)
Reference33 articles.
1. World Health Organisation. Clinical Trials 2020 Available from: https://www.who.int/topics/clinical_trials/en/.
2. Treatment of Advanced Prostate Cancer.;MY Teo;Annual review of medicine,2019
3. [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.;MS Hofman;The Lancet,2021
4. Advanced prostate cancer experimental radioactive treatment—clinical trial decision making: patient experiences.;B Viljoen;BMJ Supportive & Palliative Care.,2021
5. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden.;A Bill-Axelson;European urology,2010